How to Specify a 40:1 Myo-Inositol–D-Chiro-Inositol Blend: Ratio, Assay and Batch Checks

Quick Answer

“40:1 inositol” describes a mass ratio between myo-inositol and D-chiro-inositol. It is not a serving size and not a clinical recommendation. A usable specification says which two isomers are present, how the ratio is calculated, what tolerance applies and how each component is measured on the lot. Review the COA for two separate isomer results, do the arithmetic yourself and keep the ratio calculation on one basis. If the offer also contains folate or other nutrients, it is a premix and has to be evaluated as a finished formula rather than as a bulk raw material.

For a supplement manufacturer, “40:1 inositol” is a formulation target, not a complete raw-material specification. A defensible purchase specification says which two isomers are present, what the ratio means, how much of each is expected per gram of blend, how the supplier tests them, and what lot evidence will release the shipment. If the product also contains folate, minerals, flavors or a carrier, the buyer is dealing with a multi-ingredient premix rather than a two-component inositol blend.

That distinction answers the first sourcing question: do not approve a listing or a sample because the title says “40:1.” Confirm that the ratio is a mass ratio of myo-inositol to D-chiro-inositol (DCI), agree on individual assay limits, and obtain a batch-specific result produced by a method that can distinguish the two. The 2023 international PCOS guideline says evidence is insufficient to recommend a specific type, dose or combination of inositol for adults and adolescents with PCOS; the ratio is therefore a composition choice for a product team, not a clinical guarantee.[1]

A ratio is not a serving size—or a clinical promise

At a mass ratio of 40 parts myo-inositol to 1 part DCI, the two ingredients make 41 parts in total. In a 100 g blend, the theoretical amounts are 97.56 g myo-inositol and 2.44 g DCI, before allowing for other ingredients, assay basis, moisture or manufacturing tolerances. A serving containing 2,000 mg myo-inositol and 50 mg DCI also has a 40:1 mass ratio. The finished serving may also include excipients or other actives, so label amounts must match the finished-product design.

The word “ratio” should be written out in the purchase specification. Ask whether it is calculated from the weighed input quantities, from measured active content, or from label claims. These are not interchangeable. A recipe can use a 40:1 input ratio while the measured ratio drifts because one component is below assay, the blend includes a carrier, or production and sampling do not represent the batch evenly. If a supplier quotes a “natural 40:1 ratio,” ask for the calculation basis and evidence for the actual lot rather than adopting the phrase as a specification.

Clinical studies help explain why formulators encounter this ratio, but they do not settle a universal procurement standard. One trial compared seven MI:DCI ratios in 56 participants, with only eight people per group; the authors reported the strongest outcome in the 40:1 group.[2] A systematic review prepared for the 2023 guideline included 30 trials and concluded that evidence for inositol in PCOS was limited and inconclusive.[3] The guideline’s recommendation is the more useful boundary for product claims: do not imply that a 40:1 ingredient is the clinically preferred or guideline-recommended dose or combination.

First identify what the supplier is actually selling

Marketplace searches mix at least three different purchase objects under similar titles:

The distinction is easy to miss because retail powder listings often repeat “40:1” while adding folate or other nutrients. A finished supplement powder may be a useful benchmark for label format, but it is not evidence that its underlying active blend is sold as a clean two-component bulk ingredient. Conversely, a bulk raw listing that names both isomers does not establish that the supplier has validated the blend or can supply documentation for the destination market.

Record the material identity in plain language and by product code. State “myo-inositol and D-chiro-inositol blend” rather than “inositol”; myo-inositol is CAS 87-89-8 and D-chiro-inositol is CAS 643-12-9.[6,7] Do not treat a general inositol identity test as proof that the correct isomers are present in the intended proportions.

Put the ratio and the method on the same page

A useful specification has separate lines for identity, component assay and blend ratio. For example, it can state a target of 40:1 by weight, set an agreed tolerance around that target, and define the acceptable individual ranges for myo-inositol and DCI on an as-is or dried basis. The actual limits are a buyer–supplier agreement; there is no single universal tolerance that can be inferred from the phrase “40:1.” The specification should also say whether the ratio is calculated from the two measured component results or from the formula weights.

Ask the supplier to identify the analytical method and its scope. A method report should make clear that it can distinguish myo-inositol from DCI, identify the reference standards, state the sample-preparation and calculation basis, and show the result for each component. If the supplier provides only “total inositol” or a single purity percentage, that result cannot by itself confirm the ratio. A chromatogram can help assess selectivity, but without a defined method and traceable sample it is not batch-release evidence.

For a new supplier, request the controlled product specification, a representative COA, and the method or laboratory summary before sampling. Treat the representative COA as capability evidence, not as the result for the lot you will receive. Before shipment or release, tie the final COA to the same product code and lot number printed on the packaging and shipping documents. Requalify material changes to manufacturer, blend site, formula or test laboratory.

For US dietary supplement manufacturing, 21 CFR Part 111 requires specifications relevant to the finished supplement and component controls; it also addresses verification of component identity and the records supporting whether specifications are met.[4,5] That framework does not prescribe a universal 40:1 ratio or a particular inositol assay method. The manufacturer remains responsible for selecting suitable specifications and documenting why its testing and controls are adequate for the product.

A COA should show two numbers, not just one headline

When reviewing a lot certificate, look for the fields that let you reconstruct the blend decision:

Do the arithmetic yourself. If the lot reports 97.0% myo-inositol and 2.3% DCI on the same basis, the measured ratio is about 42.2:1, not 40:1. That calculation does not automatically mean rejection: the material may still fall within a mutually agreed ratio tolerance, or the results may use different bases. It does mean that the buyer should not accept the advertised ratio without reconciling the basis and specification. Never divide a dried-basis result by an as-is result and call the result a blend ratio.

Also separate assay from identity and purity. A high assay number does not show that the supplier tested the right isomer, and an identity pass does not show that the proportion is correct. “99%” on a product page may refer to one raw material, a total assay, or a supplier’s standard specification. Ask the seller to define the number before comparing offers.

Sampling is part of the ratio decision

Even a correct batch formula can be represented poorly by a single grab sample. A small sample taken from the top of a drum may not answer whether the delivered material is consistent throughout the package. The buyer’s sampling plan should follow its quality system and the product’s risk, with attention to the supplier’s blending process, batch size, packaging and transport. Do not assume that visible uniformity proves chemical uniformity.

During initial qualification, compare the supplier’s batch records or process summary with the actual control plan. Ask whether the two inputs are screened, pre-blended or added in a defined sequence; what mixing endpoint is used; and whether blend uniformity has been assessed at representative locations. These are qualification questions, not a claim that all inositol powders segregate. For multiple bags or drums, ask how lot identity and uniformity are controlled across containers.

For a first commercial lot, the buyer may choose a risk-based verification plan that checks a representative number of packages and compares the individual-isomer results with the approved specification. Set package count and tests through the quality unit; the ratio alone does not determine a universal sampling number. Keep a retained sample and document its collection so a later discrepancy can be investigated.

Sourcing lead

The shortest reliable approval rule is simple: approve the material only when the two isomers are identified separately, the ratio is defined on a stated basis, the test method supports that claim, and the batch result is tied to the shipment. A 40:1 headline can start a discussion. It cannot replace a specification.

Match the raw material to the finished label and process

Before approving a trial, calculate the actual masses required for the target serving and check whether the chosen form can be weighed and blended reproducibly at production scale. At 40:1, DCI is a small fraction of the active blend. That makes dispensing accuracy and premix control particularly important when a manufacturer is building a larger serving from separate single-isomer powders. A pre-blend can reduce a weighing step only if its specification and supplier controls support the declared composition.

If the raw material includes folate, vitamin D, minerals, sweeteners or flavor, treat it as a multi-ingredient premix and evaluate those components separately. Review the ingredient statement, allergen and dietary claims, contaminant controls, stability information and target-market requirements against the actual formula. A supplier’s general certificate or manufacturing-system certificate does not automatically establish that every offered product or lot meets your finished-product requirements.

For product claims, keep the evidence chain intact: a clinical study on a particular combination, dose, population and duration is not evidence that any bulk ingredient carrying the same ratio will deliver the same outcome. The guideline also notes that quality control and regulatory status can vary among inositol products.[1] Formulators should have regulatory and medical reviewers assess claims for the intended market; procurement should focus on identity, composition, specification and lot control.

A practical RFQ that prevents ratio ambiguity

Send suppliers a short, identical request so offers can be compared on the same basis:

Confirm whether you offer a two-component myo-inositol/DCI blend, separate single-isomer powders, or a finished multi-ingredient premix. State the ratio basis: target mass ratio, input formula ratio or measured active ratio. Provide the target and tolerance. Provide separate myo-inositol and DCI specifications, assay basis, identity tests and analytical methods. Share a representative COA and method summary, and confirm that shipment lots receive batch-specific results for both isomers.

Identify any carrier, excipient, processing aid or added nutrient, including its amount or specification where applicable. Confirm manufacturer and blending-site identity, product code, available pack sizes, MOQ, lead time and the documentation supplied with the order. Describe the blend-uniformity control and package/lot traceability approach, and explain how a change to formula, site or method is communicated. Quote the exact grade and quantity with the commercial terms, destination and shipping basis shown. Treat marketplace display prices as starting signals, not as a comparable landed quote.

Then compare offers by a normalized specification sheet: same identity, same ratio basis, same assay basis, same quantity and same documentation requirement. If one supplier cannot separate the two isomer results, classify the offer as unresolved rather than assuming the intended ratio. If a low-cost listing is actually a consumer supplement blend or an OEM product with added ingredients, remove it from a raw-material comparison.

References

1. Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. American Society for Reproductive Medicine, 2023. Guideline
2. Nordio M, Proietti E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. European Review for Medical and Pharmacological Sciences. 2019;23(12):5512–5521. PubMed: ratio trial
3. Fitz V, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630–1655. PubMed: systematic review
4. U.S. Food and Drug Administration. 21 CFR § 111.70 — What specifications must you establish? Electronic Code of Federal Regulations. eCFR §111.70
5. U.S. Food and Drug Administration. 21 CFR § 111.75 — What must you do to determine whether specifications are met? Electronic Code of Federal Regulations. eCFR §111.75
6. National Center for Biotechnology Information. PubChem: myo-Inositol, CAS 87-89-8. PubChem
7. United States Pharmacopeia. D-Chiro-Inositol, USP-NF Dietary Supplement Monograph, DOI: 10.31003/USPNF_M10997_02_01. USP-NF monograph